NCT01865838 is a NA clinical trial of Seprafilm (Sanofi, USA) in Thyroid Carcinoma, sponsored by National Cancer Centre, Singapore.

Who is sponsoring NCT01865838?

NCT01865838 is sponsored by National Cancer Centre, Singapore.

What drugs are being tested in NCT01865838?

Interventions in NCT01865838: Seprafilm (Sanofi, USA).

What condition does NCT01865838 study?

NCT01865838 studies Thyroid Carcinoma.

Is NCT01865838 still recruiting?

NCT01865838 is currently terminated. Last updated 10 April 2017.

Last reviewed 2017-04-10 · How we verify

NCT01865838

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study Into the Effect of Seprafilm on Post Operative Adhesions After Open Total Thyroidectomy.

Terminated NA Last updated 10 April 2017

What this trial tests

NA trial testing Seprafilm (Sanofi, USA) in Thyroid Carcinoma in 19 participants. Terminated before completion.

Timeline

1 May 2013

Primary endpoint
1 September 2014

1 September 2014

Quick facts

Lead sponsor	National Cancer Centre, Singapore
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	19
Start date	1 May 2013
Primary completion	1 September 2014
Estimated completion	1 September 2014
Sites	2 locations across Singapore

Drugs / interventions tested

Seprafilm (Sanofi, USA)

Conditions studied

Thyroid Carcinoma — all drugs for Thyroid Carcinoma →

Sponsor

National Cancer Centre, Singapore

Who can join

Adults 21 to 75, any sex, with Thyroid Carcinoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Cricoid elevation
Time frame: 1 to 14 days before the surgery, postop day 14 and 3 months postop
Trial candidates are to undergo videofluoroscopy to assess their swallowing and cricoid elevation is measured using ImageJ. * First measurement is 1 to 14 days before the surgery. * Second measurement is 14 days postop. * Third measurement is 3 months postop.

Sponsor's own description

The investigators intend to determine the role of Seprafilm, a popular anti-adhesive agent in minimising internal adhesion formation in the neck after thyroid surgery and therefore reduce swallowing discomfort experienced by patients after surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Thyroid Carcinoma

Currently open trials in the same condition.

NCT07218315 — Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma · NA · recruiting
NCT07359586 — Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia · recruiting
NCT07473518 — Thyroid Carcinoma in Cancer Patients Undergoing Radiotherapy · recruiting
NCT07072143 — An International Study on Pediatric Patients With Rare Tumors. · recruiting
NCT06146764 — CEUS Improves the Diagnostic Performance of SRSS of Thyroid Carcinoma · recruiting

Other National Cancer Centre, Singapore trials

Trials by the same sponsor.

NCT07428356 — Histotripsy for Ablation of Liver Tumours in Asia · NA · recruiting
NCT07428655 — Acceptability and Feasibility of PSC Model of Serious Illness Communication · NA · active not recruiting
NCT07116161 — Exercise Therapy and Cognitive Behavioural Therapy for Fatigue in Female Cancer Patients in Singapore · NA · recruiting
NCT06977360 — Feasibility, Acceptability and Preliminary Efficacy of the New Iteration of the Innovative Smartphone-based Care Solutio · NA · recruiting
NCT06766058 — Evaluating the Effectiveness of Aromatherapy for Alleviating Distress in Breast Cancer Patients Before Radiotherapy. · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01865838 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cancer Centre, Singapore
Last refreshed: 10 April 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01865838.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing